Integer (ITGR) 10-Q 29 Oct 20 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Oct. 02, 2020	Oct. 23, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 2, 2020
Document Transition Report	false
Entity File Number	1-16137
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-1531026
Entity Address, Address Line One	5830 Granite Parkway,
Entity Address, Address Line Two	Suite 1150
Entity Address, City or Town	Plano,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75024
City Area Code	214
Local Phone Number	618-5243
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ITGR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		32,875,166
Entity Central Index Key	0001114483
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 99,943	$ 13,535
Accounts receivable, net of provision for credit losses of $0.2 million and allowance for doubtful accounts of $2.4 million, respectively	151,201	191,985
Inventories	156,858	167,256
Contract assets	39,593	24,767
Refundable income taxes	6,521	0
Prepaid expenses and other current assets	44,537	17,852
Total current assets	498,653	415,395
Property, plant and equipment, net	249,982	246,185
Goodwill	851,679	839,617
Other intangible assets, net	759,419	775,784
Deferred income taxes	5,223	4,438
Operating lease assets	46,083	42,379
Other long-term assets	37,956	29,295
Total assets	2,448,995	2,353,093
Current liabilities:
Current portion of long-term debt	37,500	37,500
Accounts payable	55,397	64,975
Income taxes payable	1,068	3,023
Operating lease liabilities	8,287	7,507
Accrued expenses and other current liabilities	51,208	66,073
Total current liabilities	153,460	179,078
Long-term debt	801,607	777,272
Deferred income taxes	188,788	187,978
Operating lease liabilities	39,030	37,114
Other long-term liabilities	33,113	19,163
Total liabilities	1,215,998	1,200,605
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,875,166 and 32,847,017 shares issued, respectively; 32,875,166 and 32,700,471 shares outstanding, respectively	33	33
Additional paid-in capital	698,654	701,018
Treasury stock, at cost, no shares as of October 2, 2020 and 146,546 shares as of December 31, 2019	0	(8,809)
Retained earnings	502,089	440,258
Accumulated other comprehensive income	32,221	19,988
Total stockholders’ equity	1,232,997	1,152,488
Total liabilities and stockholders’ equity	$ 2,448,995	$ 2,353,093

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Oct. 02, 2020	Dec. 31, 2019
Current assets:
Allowance for doubtful accounts	$ 0.2	$ 2.4
Stockholders’ equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	32,875,166	32,847,017
Common stock, shares outstanding (in shares)	32,875,166	32,700,471
Treasury stock, shares (in shares)	0	146,546

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations- Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Income Statement [Abstract]
Sales	$ 235,942	$ 303,587	$ 804,483	$ 932,457
Cost of sales	178,009	210,201	591,985	653,477
Gross profit	57,933	93,386	212,498	278,980
Operating expenses:
Selling, general and administrative expenses (Note 10)	3,609	32,935	73,969	101,034
Research, development and engineering costs	11,892	11,729	37,879	34,720
Other operating expenses	2,674	2,241	7,631	8,239
Total operating expenses	18,175	46,905	119,479	143,993
Operating income	39,758	46,481	93,019	134,987
Interest expense, net	9,368	12,337	29,002	39,779
(Gain) loss on equity investments, net	(2,234)	(986)	(3,954)	666
Other (income) loss, net	1,224	(369)	(233)	(921)
Income from continuing operations before taxes	31,400	35,499	68,204	95,463
Provision for income taxes	1,058	4,913	6,373	15,289
Income from continuing operations	30,342	30,586	61,831	80,174
Discontinued operations:
Income from discontinued operations before taxes	0	0	0	5,316
Provision for income taxes	0	0	0	178
Income from discontinued operations	0	0	0	5,138
Net income	$ 30,342	$ 30,586	$ 61,831	$ 85,312
Basic earnings per share:
Income from continuing operations (in dollars per share)	$ 0.92	$ 0.94	$ 1.88	$ 2.46
Income from discontinued operations (in dollars per share)	0	0	0	0.16
Basic earnings per share (in dollars per share)	0.92	0.94	1.88	2.62
Diluted earnings per share:
Income from continuing operations (in dollars per share)	0.92	0.92	1.87	2.43
Income from discontinued operations (in dollars per share)	0	0	0	0.16
Diluted earnings per share (in dollars per share)	$ 0.92	$ 0.92	$ 1.87	$ 2.58
Weighted average shares outstanding:
Basic (in shares)	32,859	32,660	32,833	32,606
Diluted (in shares)	33,076	33,068	33,107	33,019

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - Unaudited - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 30,342	$ 30,586	$ 61,831	$ 85,312
Other comprehensive income (loss):
Foreign currency translation gain (loss)	16,387	(14,810)	17,303	(17,138)
Change in fair value of cash flow hedges, net of tax	1,355	(1,352)	(5,070)	(6,097)
Other comprehensive income (loss), net of tax	17,742	(16,162)	12,233	(23,235)
Comprehensive income, net of tax	$ 48,084	$ 14,424	$ 74,064	$ 62,077

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019
Cash flows from operating activities:
Net income (loss)	$ 61,831	$ 85,312
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	59,005	57,397
Debt related charges included in interest expense	3,145	5,280
Stock-based compensation	6,229	6,894
Non-cash charges related to customer bankruptcy	562	0
Non-cash lease expense	5,824	5,555
Non-cash (gain) loss on equity investments	(3,954)	666
Other non-cash gains	(184)	(1,088)
Deferred income taxes	42	(1,086)
Gain on sale of discontinued operations	0	(4,974)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	42,096	(29,962)
Inventories	10,272	(8,567)
Contract assets, prepaid expenses and other assets	(47,350)	(16,384)
Accounts payable	(5,152)	17,760
Accrued expenses and other liabilities	(13,780)	(8,988)
Income taxes	(8,347)	4,162
Net cash provided by operating activities	110,239	111,977
Cash flows from investing activities:
Acquisition of property, plant and equipment	(35,182)	(24,704)
Purchase of intangible asset	(4,607)	0
Proceeds from sale of property, plant and equipment	76	5
Purchase of equity investments	0	(417)
Acquisitions, net	(5,219)	0
Proceeds from sale of discontinued operations	0	4,734
Net cash used in investing activities	(44,932)	(20,382)
Cash flows from financing activities:
Principal payments of long-term debt	(28,125)	(97,125)
Proceeds from senior secured revolving line of credit	185,000	20,000
Payments of senior secured revolving line of credit	(135,000)	(25,000)
Proceeds from the exercise of stock options	3,123	2,654
Payment of debt issuance costs	(431)	0
Tax withholdings related to net share settlements of restricted stock unit awards	(2,869)	(2,961)
Net cash provided by (used in) financing activities	21,698	(102,432)
Effect of foreign currency exchange rates on cash and cash equivalents	(597)	(13)
Net increase (decrease) in cash and cash equivalents	86,408	(10,850)
Cash and cash equivalents, beginning of period	13,535	25,569
Cash and cash equivalents, end of period	$ 99,943	$ 14,719

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity - Unaudited - USD ($) $ in Thousands	Total	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)
Balance, beginning of period at Dec. 28, 2018	$ 1,060,493	$ 691,116	$ (8,125)	$ 344,498	$ (576)	$ 33,004
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		1,938
Stock-based compensation		6,894
Treasury shares purchased			(2,961)
Treasury shares reissued			713
Net income	85,312			85,312
Other comprehensive income (loss)	(23,235)					(23,235)
Balance, ending balance at Sep. 27, 2019	1,128,578	699,948	(10,373)	429,234		9,769
Balance, beginning of period at Jun. 28, 2019	1,111,695	697,681	(10,565)	398,648	0	25,931
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		806
Stock-based compensation		1,461
Treasury shares purchased			(56)
Treasury shares reissued			248
Net income	30,586			30,586
Other comprehensive income (loss)	(16,162)					(16,162)
Balance, ending balance at Sep. 27, 2019	1,128,578	699,948	(10,373)	429,234		9,769
Balance, beginning of period at Dec. 31, 2019	1,152,488	701,051	(8,809)	440,258	0	19,988
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		(8,593)
Stock-based compensation		6,229
Treasury shares purchased			0
Treasury shares reissued			8,809
Net income	61,831			61,831
Other comprehensive income (loss)	12,233					12,233
Balance, ending balance at Oct. 02, 2020	1,232,997	698,687	0	502,089		32,221
Balance, beginning of period at Jul. 03, 2020	1,181,401	695,684	(509)	471,747	$ 0	14,479
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		16
Stock-based compensation		2,987
Treasury shares purchased			0
Treasury shares reissued			509
Net income	30,342			30,342
Other comprehensive income (loss)	17,742					17,742
Balance, ending balance at Oct. 02, 2020	$ 1,232,997	$ 698,687	$ 0	$ 502,089		$ 32,221

Basis of Presentation

Basis of Presentation	9 Months Ended
	Oct. 02, 2020
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly-traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. On July 2, 2018, the Company completed the sale of the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”). The results of operations of the AS&O Product Line are reported as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The cash flows related to discontinued operations have not been segregated, and are included in the Condensed Consolidated Statements of Cash Flows. Unless otherwise noted specifically as discontinued operations, discussion within these notes to the Company’s condensed consolidated financial statements relates to continuing operations. See Note 16 “Discontinued Operations” for additional information related to discontinued operations. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The third quarter and first nine months of 2020 ended on October 2, 2020 and consisted of 91 days and 276 days, respectively. The third quarter and first nine months of 2019 ended on September 27, 2019 and consisted of 91 days and 273 days, respectively. Risks and Uncertainties Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business include delayed or reduced customer orders and sales, restrictions on its associates’ ability to travel or work, delays in shipments to and from certain countries, and disruptions in its supply chain. The extent to which COVID-19 impacts the Company’s operations will depend on future developments, which are highly uncertain, including, among others, the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities, to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s associates, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows. Supplier Financing Arrangements Beginning in 2020, the Company began utilizing supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. During the three and nine months ended October 2, 2020, the Company sold and de-recognized accounts receivable and collected cash of $16.2 million and $47.1 million, respectively. The costs associated with the supplier financing arrangements were not material for the three and nine months ended October 2, 2020. (1.) BASIS OF PRESENTATION (Continued) Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board ("FASB"). ASUs not yet adopted that are not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated results of operations, financial position and cash flows. With the exception of the accounting pronouncements adopted as discussed below, there have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that are of significance, or potential significance, to the Company. Recently Adopted Accounting Guidance The Company adopted ASC 326, Financial Instruments-Credit Losses , effective January 1, 2020. Under the current expected credit losses (“CECL”) model, the Company immediately recognizes an estimate of credit losses expected to occur over the life of the financial asset at the time the financial asset is originated or acquired. Estimated credit losses are determined by taking into consideration historical loss conditions, current conditions and reasonable and supportable forecasts. Changes to the expected lifetime credit losses are recognized each period. The adoption of ASC 326 did not have a material impact to the Company’s Condensed Consolidated Financial Statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting , in response to concerns about structural risks of interbank offered rates (“IBORs”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions if certain criteria are met. The ASU applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. ASU 2020-04 has not yet affected the Company’s Condensed Consolidated Financial Statements.

Business Acquisitions

Business Acquisitions	9 Months Ended
	Oct. 02, 2020
Business Combinations [Abstract]
BUSINESS ACQUISITIONS	BUSINESS ACQUISITIONS On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enables the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million over the next four years based on specified conditions being met. Based on the preliminary purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years. On October 7, 2019, the Company acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The fair value of the consideration transferred was $19.1 million, which included a cash payment of $14.9 million, which reflects a $0.1 million favorable working capital adjustment finalized in the first quarter of 2020, and $4.2 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $5.5 million if certain revenue goals are met through 2023. The assets acquired principally consist of $7.4 million of developed technology, $10.4 million of goodwill, $0.7 million of acquired property, plant and equipment, and $0.6 million of other working capital items. The developed technology intangible asset is being amortized over a useful life of 8 years. The $10.4 million of goodwill reflects a $0.1 million decrease resulting from the working capital adjustment. The company finalized the valuation and completed the purchase price allocation for the USB acquisition during the second quarter of 2020. (2.) BUSINESS ACQUISITIONS (Continued) The amount allocated to goodwill for these acquisitions is deductible for income tax purposes. The fair value of the contingent consideration was estimated using the Monte Carlo valuation approach. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. For segment reporting purposes, the results of operations and assets from these acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. For the three and nine months ended October 2, 2020, sales related to InoMec and USB were $2.2 million and $5.4 million, respectively. Earnings related to the operations consisting of the assets and liabilities acquired from InoMec and USB for the three and nine months ended October 2, 2020 were not material. During the nine months ended on October 2, 2020, direct costs of these acquisitions of $0.9 million were expensed as incurred and included in Other Operating Expenses in the Condensed Consolidated Statement of Operations. Pro forma financial information has not been presented for these acquisitions as the net effects were not significant or material to the Company’s results of operations or financial position.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Oct. 02, 2020
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION The following is supplemental information relating to the Condensed Consolidated Statements of Cash Flows (in thousands): Nine Months Ended October 2, September 27, Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 3,756 $ 5,125 Supplemental lease disclosures: Operating lease assets obtained in exchange for new or remeasured operating 8,139 — Refer to Note 16 “Discontinued Operations” for additional supplemental cash flow information pertaining to discontinued operations.

Inventories

Inventories	9 Months Ended
	Oct. 02, 2020
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories comprise the following (in thousands): October 2, December 31, Raw materials $ 78,104 $ 79,742 Work-in-process 56,160 60,042 Finished goods 22,594 27,472 Total $ 156,858 $ 167,256

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	9 Months Ended
	Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The changes in the carrying amount of goodwill by reportable segment for the nine months ended October 2, 2020 were as follows (in thousands): Medical Non- Medical Total December 31, 2019 $ 822,617 $ 17,000 $ 839,617 Foreign currency translation 7,347 — 7,347 Acquisitions and related adjustments (Note 2) 4,715 — 4,715 October 2, 2020 $ 834,679 $ 17,000 $ 851,679 Intangible Assets Intangible assets at October 2, 2020 and December 31, 2019 were as follows (in thousands): Gross Accumulated Net October 2, 2020 Definite-lived: Purchased technology and patents $ 255,475 $ (148,792) $ 106,683 Customer lists 715,589 (153,540) 562,049 Other 4,103 (3,704) 399 Total $ 975,167 $ (306,036) $ 669,131 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2019 Definite-lived: Purchased technology and patents $ 248,264 $ (138,435) $ 109,829 Customer lists 706,852 (131,185) 575,667 Other 3,503 (3,503) — Total $ 958,619 $ (273,123) $ 685,496 Indefinite-lived: Trademarks and tradenames $ 90,288 Throughout the year, the Company has evaluated the effects of the COVID-19 pandemic and its negative impact on the global economy on each of the Company’s reporting units and indefinite-lived intangible assets. Further, the collapse in the demand for oil caused by this unprecedented global health and economic crisis, coupled with oil oversupply, adversely impacted the demand for products in the Company’s Non-Medical reportable segment. In the first quarter of 2020, the Company elected to bypass a qualitative analysis of its Non-Medical reporting unit’s goodwill and performed a quantitative analysis as of April 3, 2020. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of April 3, 2020. No further impairment indicators have been identified since the first quarter of 2020 through October 2, 2020. When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. In the first quarter of 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company paid $3.5 million upon closing, and, based on the completion of certain milestones, paid an additional $0.5 million in the second quarter of 2020 and $0.5 million in the third quarter of 2020. In addition, the Company has capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. (5.) GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued) Aggregate intangible asset amortization expense comprises the following (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Cost of sales $ 3,219 $ 3,165 $ 9,660 $ 9,622 Selling, general and administrative expenses 7,080 6,617 21,234 19,845 Total intangible asset amortization expense $ 10,299 $ 9,782 $ 30,894 $ 29,467 Estimated future intangible asset amortization expense based on the carrying value as of October 2, 2020 is as follows (in thousands): Remainder of 2020 2021 2022 2023 2024 After 2024 Amortization Expense $ 10,193 41,186 40,137 38,720 37,768 501,127

Debt

Debt	9 Months Ended
	Oct. 02, 2020
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt comprises the following (in thousands): October 2, December 31, Senior secured term loan A $ 239,062 $ 267,188 Senior secured term loan B 558,286 558,286 Revolving line of credit 50,000 — Unamortized discount on term loan B and debt issuance costs (8,241) (10,702) Total debt 839,107 814,772 Current portion of long-term debt (37,500) (37,500) Total long-term debt $ 801,607 $ 777,272 The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) as of October 2, 2020, consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a term loan A facility (the “TLA Facility”), and (iii) a term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB Facility was issued at a 1% discount. On July 13, 2020, the Company amended the Senior Secured Credit Facilities (the “Amendment”) to increase the Total Net Leverage Ratio. In connection with the Amendment, the Company paid consenting lenders advanced amendment fees totaling $0.4 million during the quarter ended October 2, 2020. The Company will also pay the consenting lenders a deferred amendment fee, payable in installments of 0.03125% of the outstanding Revolving Credit Facility and TLA Facility each quarter through maturity when the Company’s Total Net Leverage Ratio equals or exceeds 3.00 to 1.00. The advanced amendment fees and deferred amendment fees, which were not material for the quarter ended October 2, 2020, are debt issuance costs which will be deferred and amortized over the remaining life of the related debt. Revolving Credit Facility The Revolving Credit Facility matures on October 27, 2022. The Revolving Credit Facility includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). As of October 2, 2020, the commitment fee on the unused portion of the Revolving Credit Facility was 0.25%. Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.50% and 2.00%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.50% and 3.00%, based on the Company’s Total Net Leverage Ratio. (6.) DEBT (Continued) As of October 2, 2020, the Company had available borrowing capacity on the Revolving Credit Facility of $143.3 million after giving effect to $50.0 million of outstanding borrowings and $6.7 million of outstanding standby letters of credit. As of October 2, 2020, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 2.41%. Term Loan Facilities The TLA Facility and TLB Facility mature on October 27, 2022. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 1.50% or (ii) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 1.00% floor. As of October 2, 2020, the interest rates on the TLA Facility and TLB Facility were 2.40% and 3.50%, respectively. Covenants The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 4.75:1.00, subject to a step down to 4.50 to 1.00 for the third fiscal quarter of 2021, and reverting to and remaining at 4.00 to 1.00 beginning with the fourth quarter of 2021 through maturity, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00:1.00. Additionally, the Net Leverage Ratio can be increased by 0.50 for up to four consecutive quarters commencing in any fiscal quarter in which the Company consummates an Eligible Adjustment Acquisition (as defined in the Amendment) with a $40 million or greater purchase price. The TLB Facility does not contain any financial maintenance covenants. As of October 2, 2020, the Company was in compliance with these financial covenants. Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2020 and through maturity, excluding any discounts or premiums, as of October 2, 2020 are as follows (in thousands): 2020 2021 2022 Future minimum principal payments $ 9,375 37,500 800,473 The Company prepaid portions of its TLB Facility during 2019. The Company recognized losses from extinguishment of debt during the three and nine months ended September 27, 2019 of $0.3 million and $1.3 million, respectively. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Oct. 02, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, restricted stock awards, restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Stock options $ 10 $ 101 $ 33 $ 304 RSUs 2,977 1,360 6,196 6,590 Total stock-based compensation expense $ 2,987 $ 1,461 $ 6,229 $ 6,894 Cost of sales $ 530 $ 168 $ 1,214 $ 766 Selling, general and administrative expenses 2,319 1,155 4,608 5,819 Research, development and engineering costs 138 69 407 193 Other operating expenses — 69 — 116 Total stock-based compensation expense $ 2,987 $ 1,461 $ 6,229 $ 6,894 (7.) STOCK-BASED COMPENSATION (Continued) The following table summarizes the Company’s stock option activity for the nine month period ended October 2, 2020: Number of Weighted Weighted Aggregate Outstanding at December 31, 2019 384,013 $ 34.96 Exercised (95,923) 32.56 Outstanding at October 2, 2020 288,090 $ 35.76 4.9 $ 6.3 Exercisable at October 2, 2020 285,540 $ 35.68 4.9 $ 6.3 During the nine months ended October 2, 2020, the Company awarded grants to certain members of its Board of Directors, certain members of management, and other employees. The Board of Directors received grants of time-based RSUs that vest in four substantially equal quarterly installments beginning on the three-month anniversary of the grant date. The members of management and other employees received either time-based RSUs or a mix of time-based RSUs and performance-based RSUs (“PRSUs”). The time-based RSUs vest ratably, subject to the recipient’s continuous service to the Company over a period of generally three years from the grant date. For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of financial performance or market-based conditions. The financial performance condition is based on the Company’s sales targets. The market-based conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three The Company uses a Monte Carlo simulation model to determine the grant-date fair value of awards with TSR-based performance conditions. The grant-date fair value of all other RSUs is equal to the closing market price of Integer common stock on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: Nine Months Ended October 2, September 27, Weighted average fair value $ 107.27 $ 117.03 Risk-free interest rate 1.29 % 2.46 % Expected volatility 30 % 40 % Expected life (in years) 2.9 2.8 Expected dividend yield — % — % The valuation of the TSR portion of the PRSUs granted during 2020 also reflects a weighted average illiquidity discount of 8.00%, determined utilizing the Chaffe model valuation technique, and related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting. (7.) STOCK-BASED COMPENSATION (Continued) The following table summarizes time-vested RSU activity for the nine month period ended October 2, 2020: Time-Vested Weighted Nonvested at December 31, 2019 205,223 $ 64.75 Granted 143,122 83.94 Vested (83,469) 59.60 Forfeited (12,343) 75.28 Nonvested at October 2, 2020 252,533 $ 76.81 The following table summarizes PRSU activity for the nine month period ended October 2, 2020: Performance- Weighted Nonvested at December 31, 2019 191,592 $ 56.30 Granted 67,268 95.06 Vested (35,363) 31.17 Forfeited (4,106) 51.54 Nonvested at October 2, 2020 219,391 $ 72.33

Other Operating Expenses

Other Operating Expenses	9 Months Ended
	Oct. 02, 2020
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES	OTHER OPERATING EXPENSES Other Operating Expenses consists of the following (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Strategic reorganization and alignment $ — $ 962 $ 686 $ 4,352 Manufacturing alignment to support growth 36 515 224 1,661 2020 restructuring plan 858 — 2,275 — Acquisition and integration expenses 107 — 510 — Other general expenses 1,673 764 3,936 2,226 Total other operating expenses $ 2,674 $ 2,241 $ 7,631 $ 8,239 Strategic reorganization and alignment As a result of the strategic review of its customers, competitors and markets, the Company began taking steps in 2017 to better align its resources in order to enhance the profitability of its portfolio of products. These initiatives include improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. During the nine months ended October 2, 2020, the Company incurred charges relating to these initiatives, which primarily included severance recorded within the Medical segment. As of October 2, 2020, total expense incurred for these initiatives since inception, including amounts reported in discontinued operations, was $23.0 million. These actions were completed during the second quarter of 2020. (8.) OTHER OPERATING EXPENSES (Continued) Manufacturing alignment to support growth In 2017, the Company initiated several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company’s facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of approximately $6 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of October 2, 2020, total expense incurred for this initiative since inception was $5.8 million. These actions were substantially complete at the end of 2019 and will be completed by the end of 2020. 2020 restructuring plan The Company’s 2020 restructuring plan mainly consists of costs associated with executing on its sales force excellence, manufacturing excellence and business process excellence imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the 2020 restructuring plan of between approximately $2 million to $3 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2020 restructuring plan are expected to be primarily recorded within the Medical segment. As of October 2, 2020, total expense incurred for this initiative since inception was $2.3 million, which was primarily severance. These actions are expected to be substantially complete by the end of 2020. The following table summarizes the change in accrued liabilities, presented within Accrued Expense and Other Current Liabilities on the Condensed Consolidated Balance Sheets, related to the initiatives described above (in thousands): Severance and Retention Other Total December 31, 2019 $ 1,389 $ 596 $ 1,985 Restructuring charges 2,166 1,019 3,185 Cash payments (3,483) (1,519) (5,002) October 2, 2020 $ 72 $ 96 $ 168 Acquisition and integration expenses During the nine months ended October 2, 2020, acquisition and integration expenses included $1.0 million of expenses related to the acquisition of certain assets and liabilities of InoMec and USB, and a $0.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities. Acquisition and integration costs primarily include direct acquisition costs incurred which consist of professional fees and other costs. Other general expenses During the nine months ended October 2, 2020 and September 27, 2019, the Company recorded expenses related to other initiatives not described above, which relate primarily to actions to align labor with customer demand as a result of COVID-19 and the decline of the energy market, integration and operational initiatives to reduce future costs and improve efficiencies. The 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses and expenses related to the restructuring of certain legal entities of the Company.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 02, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate. The Company’s effective tax rate for continuing operations for the third quarter of 2020 was 3.4% on $31.4 million of income from continuing operations before taxes compared to 13.8% on $35.5 million of income from continuing operations before taxes for the same period in 2019. The Company’s effective tax rate for continuing operations for the first nine months of 2020 was 9.3% on $68.2 million of income from continuing operations before taxes compared to 16.0% on $95.5 million of income from continuing operations before taxes for the same period in 2019. The difference between the Company’s effective tax rates and the U.S. federal statutory income tax rate of 21% for the third quarter and first nine months of 2020 and 2019 is primarily attributable to discrete tax benefits, as well as the estimated net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, the estimated net impact of the Global Intangible Low-Taxed Income (“GILTI”) tax, and the availability of certain tax credits. The Company recorded discrete tax benefits of $4.9 million and $5.9 million, respectively, for the third quarter and first nine months of 2020, compared to discrete tax benefits of $2.3 million and $4.4 million, respectively, for the third quarter and first nine months of 2019. The discrete tax benefits for 2020 are predominately related to excess tax benefits recognized upon vesting of RSUs or exercise of stock options, favorable return to provision adjustments related to the 2019 tax year, the net impact of a tax restructuring of the Company’s Malaysian legal entity, and the impact of Final Treasury Regulations issued in July 2020 for GILTI, and Foreign Derived Intangible Income. As of October 2, 2020 and December 31, 2019, the Company had unrecognized tax benefits from continuing operations of approximately $5.0 million and $4.4 million, respectively. It is reasonably possible that a reduction of up to $3.9 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. As of October 2, 2020 and December 31, 2019, approximately $5.0 million and $4.4 million, respectively, of the unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized. In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The CARES Act provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December 31, 2021 and the remaining 50% due December 31, 2022. As allowed under the CARES Act, the Company is deferring payment of the employer portion of Social Security taxes through the end of 2020. As of October 2, 2020, the Company had deferred a total of $6.5 million of payroll taxes in the second and third quarters to be paid equally in the fourth quarters of 2021 and 2022. The deferred payroll taxes are included within Other long-term liabilities on the Condensed Consolidated Balance Sheets. For the nine months ended October 2, 2020, there were no material income tax impacts to our Condensed Consolidated Financial Statements as it relates to COVID-19 measures. The Company continues to monitor additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service and others.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 02, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingent Consideration Arrangements The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information. Litigation The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. The Company records a contingent gain for litigation when all of the following conditions have been met: (a) the amount to be paid to the Company is known, (b) there is no potential for appeal or reversal, and (c) collectability is reasonably assured. In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Following four trials, the Company was awarded $27.8 million in damages. In August 2019, AVX filed a notice of appeal with the United States Court of Appeals for the Federal Circuit and the Company subsequently filed a notice of cross-appeal. In July 2020, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, the judgment in favor of the Company. The Company determined that a contingent gain was realizable as of October 2, 2020 and recorded an asset of $28.9 million, including damages and post-judgment interest, within Prepaid expenses and other current assets. In addition, a liability of $0.7 million was recorded as of October 2, 2020 for certain related expenses which are included in Accrued expenses and other current liabilities. The Company recognized a net gain on patent litigation of $28.2 million during the third quarter of 2020. On October 15, 2020, the Company received a partial payment of $28.3 million and received the balance of $0.6 million on October 26, 2020. The Company used the proceeds to pay down a portion of its Revolving Credit Facility. Selling, general and administrative expenses The net gain on patent litigation of $28.2 million is recorded in Selling, g eneral and administrative expenses in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 2, 2020. Product Warranties The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The product warranty liability is presented within Accrued Expense and Other Current Liabilities on the Condensed Consolidated Balance Sheets. The change in product warranty liability was comprised of the following (in thousands): December 31, 2019 $ 1,933 Additions to warranty reserve, net of reversals (156) Adjustments to pre-existing warranties (119) Warranty claims settled (1,323) October 2, 2020 $ 335

Earnings Per Share (EPS)

Earnings Per Share (EPS)	9 Months Ended
	Oct. 02, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Numerator for basic and diluted EPS: Income from continuing operations $ 30,342 $ 30,586 $ 61,831 $ 80,174 Income from discontinued operations — — — 5,138 Net income $ 30,342 $ 30,586 $ 61,831 $ 85,312 Denominator for basic and diluted EPS: Weighted average shares outstanding - Basic 32,859 32,660 32,833 32,606 Dilutive effect of share-based awards 217 408 274 413 Weighted average shares outstanding - Diluted 33,076 33,068 33,107 33,019 Basic earnings per share: Income from continuing operations $ 0.92 $ 0.94 $ 1.88 $ 2.46 Income from discontinued operations — — — 0.16 Basic earnings per share 0.92 0.94 1.88 2.62 Diluted earnings per share: Income from continuing operations $ 0.92 $ 0.92 $ 1.87 $ 2.43 Income from discontinued operations — — — 0.16 Diluted earnings per share 0.92 0.92 1.87 2.58 The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Time-vested stock options, RSAs and RSUs 145 — 134 29 Performance-vested restricted stock and PRSUs 167 50 93 48

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Oct. 02, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY The following is a summary of the number of shares of common stock issued, treasury stock and common stock outstanding for the nine month periods ended October 2, 2020 and September 27, 2019: Nine Months Ended October 2, 2020 Nine Months Ended September 27, 2019 Issued Treasury Stock Outstanding Issued Treasury Stock Outstanding Balance, beginning of period 32,847,017 (146,546) 32,700,471 32,624,494 (151,327) 32,473,167 Stock options exercised 21,327 74,596 95,923 116,904 — 116,904 RSAs issued, net of forfeitures, 6,822 71,950 78,772 99,785 (21,229) 78,556 Balance, end of period 32,875,166 — 32,875,166 32,841,183 (172,556) 32,668,627 Accumulated Other Comprehensive Income (Loss) (“AOCI”) comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax July 3, 2020 $ (912) $ (10,491) $ 23,555 $ 12,152 $ 2,327 $ 14,479 Unrealized gain on cash flow hedges — 565 — 565 (118) 447 Realized loss on foreign currency hedges — 84 — 84 (18) 66 Realized loss on interest rate swap hedge — 1,066 — 1,066 (224) 842 Foreign currency translation gain — — 16,387 16,387 — 16,387 October 2, 2020 $ (912) $ (8,776) $ 39,942 $ 30,254 $ 1,967 $ 32,221 December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (9,416) — (9,416) 1,978 (7,438) Realized loss on foreign currency hedges — 567 — 567 (119) 448 Realized loss on interest rate swap hedges — 2,431 — 2,431 (511) 1,920 Foreign currency translation gain — — 17,303 17,303 — 17,303 October 2, 2020 $ (912) $ (8,776) $ 39,942 $ 30,254 $ 1,967 $ 32,221 June 28, 2019 $ (295) $ (2,567) $ 28,211 $ 25,349 $ 582 $ 25,931 Unrealized loss on cash flow hedges — (1,459) — (1,459) 307 (1,152) Realized loss on foreign currency hedges — 191 — 191 (40) 151 Realized gain on interest rate swap hedges — (444) — (444) 93 (351) Foreign currency translation loss — — (14,810) (14,810) — (14,810) September 27, 2019 $ (295) $ (4,279) $ 13,401 $ 8,827 $ 942 $ 9,769 December 28, 2018 $ (295) $ 3,439 $ 30,539 $ 33,683 $ (679) $ 33,004 Unrealized loss on cash flow hedges — (6,028) — (6,028) 1,266 (4,762) Realized loss on foreign currency hedges — 157 — 157 (33) 124 Realized gain on interest rate swap hedge — (1,847) — (1,847) 388 (1,459) Foreign currency translation loss — — (17,138) (17,138) — (17,138) September 27, 2019 $ (295) $ (4,279) $ 13,401 $ 8,827 $ 942 $ 9,769

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	9 Months Ended
	Oct. 02, 2020
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet. The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant October 2, 2020 Assets: Foreign currency contracts $ 98 $ — $ 98 $ — Liabilities: Foreign currency contracts 836 — 836 — Liabilities: Interest rate swaps 8,038 — 8,038 — Liabilities: Contingent consideration 5,401 — — 5,401 December 31, 2019 Assets: Foreign currency contracts $ 710 $ — $ 710 $ — Liabilities: Interest rate swaps 3,068 — 3,068 — Liabilities: Contingent consideration 4,200 — — 4,200 Interest Rate Swaps The Company periodically enters into interest rate swap agreements in order to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings. Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of October 2, 2020 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2020 Jun 2023 2.1785 % 0.1448 % $ (8,038) Other long-term liabilities (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2019 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2017 Jun 2020 1.1325 % 1.7920 % $ 543 Accrued expenses and other current liabilities 65,000 Jul 2019 Jul 2020 1.8900 1.7920 (72) Accrued expenses and other current liabilities 400,000 Apr 2019 Apr 2020 2.4150 1.7101 (730) Accrued expenses and other current liabilities 200,000 Jun 2020 Jun 2023 2.1785 (a) (2,809) Other long-term liabilities __________ (a) The interest rate swap did not take effect until June 2020. Foreign Currency Contracts The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of October 2, 2020 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 7,666 Jul 2020 Dec 2020 0.0491 MXN Peso $ (519) Accrued expenses and other current liabilities 2,290 Mar 2020 Dec 2020 0.0241 UYU Peso (52) Prepaid expenses and other current assets 18,514 Nov 2020 Sep 2021 1.1944 Euro (274) Accrued expenses and other current liabilities 10,224 Jan 2021 Sep 2021 0.0454 MXN Peso (109) Accrued expenses and other current liabilities 2,343 Nov 2020 Nov 2020 1.1717 Euro 2 Accrued expenses and other current liabilities 2,656 Jan 2021 Mar 2021 0.0443 MXN Peso 64 Accrued expenses and other current liabilities 3,252 Jan 2021 Aug 2021 0.0232 UYU Peso 150 Prepaid expenses and other current assets Information regarding outstanding foreign currency contracts designated as cash flow hedges as of December 31, 2019 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 11,166 Jan 2020 Jun 2020 0.0490 MXN Peso $ 710 Prepaid expenses and other current assets Contingent Consideration The Company estimated the original fair value of the contingent consideration liabilities for the InoMec and USB acquisitions using a Monte Carlo simulation in order to forecast the value of the potential future payment. In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The assumptions used in the determination of fair value of contingent consideration liabilities are not observable in the market, thus representing a Level 3 measurement within the fair value hierarchy. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities in the Condensed Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Company’s Condensed Consolidated Statements of Operations. For the February 19, 2020 InoMec acquisition, additional purchase price payments ranging from zero to $3.5 million are contingent upon the achievement of certain revenue targets through February 29, 2024. At the date of acquisition, the Company estimated the original fair value of the contingent consideration to be $1.7 million. At October 2, 2020, the estimated fair value of the contingent consideration associated with the InoMec acquisition was $1.7 million. (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) For the October 7, 2019 USB acquisition, additional purchase price payments ranging from zero to $5.5 million are contingent upon the achievement of certain revenue targets through December 31, 2023. At the date of acquisition, the Company estimated the original fair value of the contingent consideration to be $4.2 million. During the nine months ended October 2, 2020, the Company recognized a gain from the fair value adjustment of contingent consideration of $0.5 million. The fair value adjustment for the nine months ended October 2, 2020 was due to a change in the timing of the projected future revenues, rise in the estimated revenue volatility, and increase in the discount rate used to calculate the present value of the contingent consideration liability. At October 2, 2020, the estimated fair value of the contingent consideration associated with the USB acquisition was $3.7 million. During the first quarter of 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. At the date of acquisition, the Company estimated the original fair value of the contingent consideration to be $1.0 million. The Company paid made milestone payments of $0.5 million during the second and third quarters of 2020 to settle this contingent consideration arrangement. The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the nine months ended October 2, 2020 (in thousands): December 31, 2019 $ 4,200 Contingent consideration liabilities recorded for acquisitions 2,700 Fair value adjustment included in Other operating expenses (500) Settlements (1,000) Foreign currency translation 1 October 2, 2020 $ 5,401 As of October 2, 2020, the estimated fair value of the contingent consideration was $5.4 million, of which $1.2 million is included as current contingent consideration and $4.2 million is included in non-current contingent consideration in the Condensed Consolidated Balance Sheets. Derivative Instruments with Hedge Accounting Designation The following tables present the effect of cash flow hedge derivative instruments on other comprehensive income (loss) (“OCI”), AOCI and the Company’s Condensed Consolidated Statement of Operations for the three and nine months ended October 2, 2020 and September 27, 2019 (in thousands): Three Months Ended October 2, 2020 September 27, 2019 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 235,942 $ 590 $ 303,587 $ (500) Cost of sales 178,009 (651) 210,201 309 Operating expenses 18,175 (23) 46,905 — Interest expense 9,368 (1,066) 12,337 444 Nine Months Ended October 2, 2020 September 27, 2019 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 804,483 $ 549 $ 932,457 $ (1,294) Cost of sales 591,985 (1,059) 653,477 1,137 Operating expenses 119,479 (57) 143,993 — Interest expense 29,002 (2,431) 39,779 1,847 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Unrealized Gain (Loss) Recognized in OCI Realized Gain (Loss) Reclassified from AOCI Three months ended, Location in Statement of Operations Three months ended, October 2, September 27, October 2, September 27, Interest rate swap $ (11) $ (991) Interest expense $ (1,066) $ 444 Foreign exchange forwards 68 (400) Sales 590 (500) Foreign exchange forwards 451 (68) Cost of sales (651) 309 Foreign exchange forwards 57 — Operating expenses (23) — Nine Months Ended Location in Statement of Operations Nine Months Ended October 2, September 27, October 2, September 27, Interest rate swaps $ (7,401) $ (6,590) Interest expense $ (2,431) $ 1,847 Foreign exchange contracts 277 (1,099) Sales 549 (1,294) Foreign exchange contracts (2,277) 1,661 Cost of sales (1,059) 1,137 Foreign exchange forwards (15) — Operating expenses (57) — The Company expects to reclassify net losses totaling $4.3 million related to its cash flow hedges from AOCI into earnings during the next twelve months. Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments. Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other Long-Term Assets on the Condensed Consolidated Balance Sheets. Non-marketable equity securities are equity securities without readily determinable fair value. The Company has elected the practicability exception to use an alternative approach that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. Equity investments comprise the following (in thousands): October 2, December 31, Equity method investment $ 19,718 $ 16,167 Non-marketable equity securities 6,092 6,092 Total equity investments $ 25,810 $ 22,259 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) The components of (Gain) Loss on Equity Investments, Net for each period were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Equity method investment income $ (2,234) $ (986) $ (3,954) $ (909) Impairment charges — — — 1,575 Total (gain) loss on equity investments, net $ (2,234) $ (986) $ (3,954) $ 666 The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of October 2, 2020, the Company owned 6.6% of this fund.

Segment Information

Segment Information	9 Months Ended
	Oct. 02, 2020
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . For purposes of segment reporting, intercompany sales between segments are not material. The following table presents sales from continuing operations by product line (in thousands). Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Segment sales from continuing operations by product line: Medical Cardio & Vascular $ 124,596 $ 148,581 $ 432,885 $ 451,552 Cardiac & Neuromodulation 72,909 106,533 252,404 337,932 Advanced Surgical, Orthopedics & Portable Medical 30,179 34,310 92,041 98,544 Total Medical 227,684 289,424 777,330 888,028 Non-Medical 8,258 14,163 27,153 44,429 Total sales from continuing operations $ 235,942 $ 303,587 $ 804,483 $ 932,457 The following table presents income from continuing operations for the Company’s reportable segments (in thousands). Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Segment income from continuing operations: Medical $ 28,777 $ 62,648 $ 120,903 $ 182,734 Non-Medical 1,214 3,318 4,894 12,927 Total segment income 29,991 65,966 125,797 195,661 Unallocated operating income (expenses) (a) 9,767 (19,485) (32,778) (60,674) Operating income 39,758 46,481 93,019 134,987 Unallocated expenses, net (8,358) (10,982) (24,815) (39,524) Income from continuing operations before taxes $ 31,400 $ 35,499 $ 68,204 $ 95,463

Revenue From Contracts With Cus

Revenue From Contracts With Customers	9 Months Ended
	Oct. 02, 2020
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregated Revenue In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment’s results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 14, “Segment Information.” Revenue recognized from products and services transferred to customers over time for the three and nine months ended October 2, 2020 represented 30% and 29%, respectively, of total revenue. Revenue recognized from products and services transferred to customers over time for the three and nine months ended September 27, 2019 represented 10% and 11%, respectively, of total revenue. All revenue recognized from products and services transferred to customers over time during the periods presented was within the Medical segment. The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues. Three Months Ended October 2, 2020 September 27, 2019 Customer Medical Non-Medical Medical Non-Medical Customer A 16% * 20% * Customer B 17% * 18% * Customer C 17% * 13% * Customer D * 25% * 22% Customer F * 11% * * Customer G * * * 12% All other customers 50% 64% 49% 66% Nine Months Ended October 2, 2020 September 27, 2019 Customer Medical Non-Medical Medical Non-Medical Customer A 20% * 22% * Customer B 16% * 18% * Customer C 15% * 12% * Customer D * 22% * 24% Customer E * 11% * * All other customers 49% 67% 48% 76% __________ * Less than 10% of segment’s total revenues for the period. The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped. Three Months Ended October 2, 2020 September 27, 2019 Ship to Location Medical Non-Medical Medical Non-Medical United States 58% 66% 55% 61% South Korea * 11% * * Puerto Rico * * 11% * Canada * * * 12% All other countries 42% 23% 34% 27% (15.) REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued) Nine Months Ended October 2, 2020 September 27, 2019 Ship to Location Medical Non-Medical Medical Non-Medical United States 56% 54% 56% 58% Canada * 11% * 13% United Kingdom * 10% * * Puerto Rico * * 13% * All other countries 44% 25% 31% 29% __________ * Less than 10% of segment’s total revenues for the period. Contract Balances The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): October 2, December 31, Contract assets $ 39,593 $ 24,767 Contract liabilities included in accrued expenses and other current liabilities 1,927 1,975 Contract assets at October 2, 2020, increased $14.8 million from December 31, 2019, due to a new contract with a customer where control is transferred over time. During the three and nine months ended October 2, 2020, the Company recognized $0.2 million and $1.3 million, respectively, of revenue that was included in the contract liability balance as of December 31, 2019. During the three and nine months ended September 27, 2019, the Company recognized $0.4 million and $0.8 million, respectively, of revenue that was included in the contract liability balance as of December 28, 2018.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Oct. 02, 2020
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS On July 2, 2018, the Company completed the sale of its AS&O Product Line to Viant. In connection with the sale, the parties executed a transition services agreement whereby the Company would provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant paid Integer for these services as specified in the transition services agreement, which were complete as of June 28, 2019. The Company recognized $2.9 million of income under the transition services agreement for the performance of services during the nine months ended September 27, 2019, of which $0.1 million is within Cost of sales and $2.8 million, is within Selling, general and administrative expenses. During the quarter ended June 28, 2019, the Company received $4.8 million due to a net working capital adjustment agreed to with Viant. This was recognized as gain on sale from discontinued operations during the quarter ended June 28, 2019. The operating results of the AS&O Product Line have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The discontinued operations of the AS&O Product Line are reported in the Medical segment. Income from discontinued operations net of taxes, were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Gain on sale of discontinued operations $ — $ — $ — $ (4,974) Other income, net — — — (342) Provision for income taxes — — — 178 Income from discontinued operations $ — $ — $ — $ 5,138 Cash flow information from discontinued operations was as follows (in thousands): Nine Months Ended October 2, September 27, Cash used in operating activities $ — $ (58) Cash provided by investing activities — 4,734

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Oct. 02, 2020
Accounting Policies [Abstract]
Interim Basis of Accounting	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board ("FASB"). ASUs not yet adopted that are not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated results of operations, financial position and cash flows. With the exception of the accounting pronouncements adopted as discussed below, there have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that are of significance, or potential significance, to the Company. Recently Adopted Accounting Guidance The Company adopted ASC 326, Financial Instruments-Credit Losses , effective January 1, 2020. Under the current expected credit losses (“CECL”) model, the Company immediately recognizes an estimate of credit losses expected to occur over the life of the financial asset at the time the financial asset is originated or acquired. Estimated credit losses are determined by taking into consideration historical loss conditions, current conditions and reasonable and supportable forecasts. Changes to the expected lifetime credit losses are recognized each period. The adoption of ASC 326 did not have a material impact to the Company’s Condensed Consolidated Financial Statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting , in response to concerns about structural risks of interbank offered rates (“IBORs”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions if certain criteria are met. The ASU applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. ASU 2020-04 has not yet affected the Company’s Condensed Consolidated Financial Statements.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate.
Cost And Equity Method Investments	The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other Long-Term Assets on the Condensed Consolidated Balance Sheets. Non-marketable equity securities

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Oct. 02, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	The following is supplemental information relating to the Condensed Consolidated Statements of Cash Flows (in thousands): Nine Months Ended October 2, September 27, Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 3,756 $ 5,125 Supplemental lease disclosures: Operating lease assets obtained in exchange for new or remeasured operating 8,139 —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 02, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories comprise the following (in thousands): October 2, December 31, Raw materials $ 78,104 $ 79,742 Work-in-process 56,160 60,042 Finished goods 22,594 27,472 Total $ 156,858 $ 167,256

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	9 Months Ended
	Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment for the nine months ended October 2, 2020 were as follows (in thousands): Medical Non- Medical Total December 31, 2019 $ 822,617 $ 17,000 $ 839,617 Foreign currency translation 7,347 — 7,347 Acquisitions and related adjustments (Note 2) 4,715 — 4,715 October 2, 2020 $ 834,679 $ 17,000 $ 851,679
Schedule of Finite-Lived Intangible Assets, Major Class	Intangible assets at October 2, 2020 and December 31, 2019 were as follows (in thousands): Gross Accumulated Net October 2, 2020 Definite-lived: Purchased technology and patents $ 255,475 $ (148,792) $ 106,683 Customer lists 715,589 (153,540) 562,049 Other 4,103 (3,704) 399 Total $ 975,167 $ (306,036) $ 669,131 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2019 Definite-lived: Purchased technology and patents $ 248,264 $ (138,435) $ 109,829 Customer lists 706,852 (131,185) 575,667 Other 3,503 (3,503) — Total $ 958,619 $ (273,123) $ 685,496 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Indefinite-Lived Intangible Assets	Intangible assets at October 2, 2020 and December 31, 2019 were as follows (in thousands): Gross Accumulated Net October 2, 2020 Definite-lived: Purchased technology and patents $ 255,475 $ (148,792) $ 106,683 Customer lists 715,589 (153,540) 562,049 Other 4,103 (3,704) 399 Total $ 975,167 $ (306,036) $ 669,131 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2019 Definite-lived: Purchased technology and patents $ 248,264 $ (138,435) $ 109,829 Customer lists 706,852 (131,185) 575,667 Other 3,503 (3,503) — Total $ 958,619 $ (273,123) $ 685,496 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense comprises the following (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Cost of sales $ 3,219 $ 3,165 $ 9,660 $ 9,622 Selling, general and administrative expenses 7,080 6,617 21,234 19,845 Total intangible asset amortization expense $ 10,299 $ 9,782 $ 30,894 $ 29,467
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the carrying value as of October 2, 2020 is as follows (in thousands): Remainder of 2020 2021 2022 2023 2024 After 2024 Amortization Expense $ 10,193 41,186 40,137 38,720 37,768 501,127

Debt (Tables)

Debt (Tables)	9 Months Ended
	Oct. 02, 2020
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt comprises the following (in thousands): October 2, December 31, Senior secured term loan A $ 239,062 $ 267,188 Senior secured term loan B 558,286 558,286 Revolving line of credit 50,000 — Unamortized discount on term loan B and debt issuance costs (8,241) (10,702) Total debt 839,107 814,772 Current portion of long-term debt (37,500) (37,500) Total long-term debt $ 801,607 $ 777,272
Schedule of Maturities of Long-term Debt	Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2020 and through maturity, excluding any discounts or premiums, as of October 2, 2020 are as follows (in thousands): 2020 2021 2022 Future minimum principal payments $ 9,375 37,500 800,473

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Oct. 02, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Stock options $ 10 $ 101 $ 33 $ 304 RSUs 2,977 1,360 6,196 6,590 Total stock-based compensation expense $ 2,987 $ 1,461 $ 6,229 $ 6,894 Cost of sales $ 530 $ 168 $ 1,214 $ 766 Selling, general and administrative expenses 2,319 1,155 4,608 5,819 Research, development and engineering costs 138 69 407 193 Other operating expenses — 69 — 116 Total stock-based compensation expense $ 2,987 $ 1,461 $ 6,229 $ 6,894
Schedule of Share-based Compensation, Stock Options Activity	The following table summarizes the Company’s stock option activity for the nine month period ended October 2, 2020: Number of Weighted Weighted Aggregate Outstanding at December 31, 2019 384,013 $ 34.96 Exercised (95,923) 32.56 Outstanding at October 2, 2020 288,090 $ 35.76 4.9 $ 6.3 Exercisable at October 2, 2020 285,540 $ 35.68 4.9 $ 6.3
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: Nine Months Ended October 2, September 27, Weighted average fair value $ 107.27 $ 117.03 Risk-free interest rate 1.29 % 2.46 % Expected volatility 30 % 40 % Expected life (in years) 2.9 2.8 Expected dividend yield — % — %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested RSU activity for the nine month period ended October 2, 2020: Time-Vested Weighted Nonvested at December 31, 2019 205,223 $ 64.75 Granted 143,122 83.94 Vested (83,469) 59.60 Forfeited (12,343) 75.28 Nonvested at October 2, 2020 252,533 $ 76.81 The following table summarizes PRSU activity for the nine month period ended October 2, 2020: Performance- Weighted Nonvested at December 31, 2019 191,592 $ 56.30 Granted 67,268 95.06 Vested (35,363) 31.17 Forfeited (4,106) 51.54 Nonvested at October 2, 2020 219,391 $ 72.33

Other Operating Expenses (Table

Other Operating Expenses (Tables)	9 Months Ended
	Oct. 02, 2020
Other Income and Expenses [Abstract]
Schedule of Other Operating Cost and Expense By Component	Other Operating Expenses consists of the following (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Strategic reorganization and alignment $ — $ 962 $ 686 $ 4,352 Manufacturing alignment to support growth 36 515 224 1,661 2020 restructuring plan 858 — 2,275 — Acquisition and integration expenses 107 — 510 — Other general expenses 1,673 764 3,936 2,226 Total other operating expenses $ 2,674 $ 2,241 $ 7,631 $ 8,239
Schedule of Changes in Accrued Liabilities	The following table summarizes the change in accrued liabilities, presented within Accrued Expense and Other Current Liabilities on the Condensed Consolidated Balance Sheets, related to the initiatives described above (in thousands): Severance and Retention Other Total December 31, 2019 $ 1,389 $ 596 $ 1,985 Restructuring charges 2,166 1,019 3,185 Cash payments (3,483) (1,519) (5,002) October 2, 2020 $ 72 $ 96 $ 168

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Oct. 02, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands): December 31, 2019 $ 1,933 Additions to warranty reserve, net of reversals (156) Adjustments to pre-existing warranties (119) Warranty claims settled (1,323) October 2, 2020 $ 335

Earnings Per Share (EPS) (Table

Earnings Per Share (EPS) (Tables)	9 Months Ended
	Oct. 02, 2020
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Numerator for basic and diluted EPS: Income from continuing operations $ 30,342 $ 30,586 $ 61,831 $ 80,174 Income from discontinued operations — — — 5,138 Net income $ 30,342 $ 30,586 $ 61,831 $ 85,312 Denominator for basic and diluted EPS: Weighted average shares outstanding - Basic 32,859 32,660 32,833 32,606 Dilutive effect of share-based awards 217 408 274 413 Weighted average shares outstanding - Diluted 33,076 33,068 33,107 33,019 Basic earnings per share: Income from continuing operations $ 0.92 $ 0.94 $ 1.88 $ 2.46 Income from discontinued operations — — — 0.16 Basic earnings per share 0.92 0.94 1.88 2.62 Diluted earnings per share: Income from continuing operations $ 0.92 $ 0.92 $ 1.87 $ 2.43 Income from discontinued operations — — — 0.16 Diluted earnings per share 0.92 0.92 1.87 2.58
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Time-vested stock options, RSAs and RSUs 145 — 134 29 Performance-vested restricted stock and PRSUs 167 50 93 48

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Oct. 02, 2020
Stockholders' Equity Note [Abstract]
Schedule of Common Stock Outstanding Roll Forward	The following is a summary of the number of shares of common stock issued, treasury stock and common stock outstanding for the nine month periods ended October 2, 2020 and September 27, 2019: Nine Months Ended October 2, 2020 Nine Months Ended September 27, 2019 Issued Treasury Stock Outstanding Issued Treasury Stock Outstanding Balance, beginning of period 32,847,017 (146,546) 32,700,471 32,624,494 (151,327) 32,473,167 Stock options exercised 21,327 74,596 95,923 116,904 — 116,904 RSAs issued, net of forfeitures, 6,822 71,950 78,772 99,785 (21,229) 78,556 Balance, end of period 32,875,166 — 32,875,166 32,841,183 (172,556) 32,668,627
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) (“AOCI”) comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax July 3, 2020 $ (912) $ (10,491) $ 23,555 $ 12,152 $ 2,327 $ 14,479 Unrealized gain on cash flow hedges — 565 — 565 (118) 447 Realized loss on foreign currency hedges — 84 — 84 (18) 66 Realized loss on interest rate swap hedge — 1,066 — 1,066 (224) 842 Foreign currency translation gain — — 16,387 16,387 — 16,387 October 2, 2020 $ (912) $ (8,776) $ 39,942 $ 30,254 $ 1,967 $ 32,221 December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (9,416) — (9,416) 1,978 (7,438) Realized loss on foreign currency hedges — 567 — 567 (119) 448 Realized loss on interest rate swap hedges — 2,431 — 2,431 (511) 1,920 Foreign currency translation gain — — 17,303 17,303 — 17,303 October 2, 2020 $ (912) $ (8,776) $ 39,942 $ 30,254 $ 1,967 $ 32,221 June 28, 2019 $ (295) $ (2,567) $ 28,211 $ 25,349 $ 582 $ 25,931 Unrealized loss on cash flow hedges — (1,459) — (1,459) 307 (1,152) Realized loss on foreign currency hedges — 191 — 191 (40) 151 Realized gain on interest rate swap hedges — (444) — (444) 93 (351) Foreign currency translation loss — — (14,810) (14,810) — (14,810) September 27, 2019 $ (295) $ (4,279) $ 13,401 $ 8,827 $ 942 $ 9,769 December 28, 2018 $ (295) $ 3,439 $ 30,539 $ 33,683 $ (679) $ 33,004 Unrealized loss on cash flow hedges — (6,028) — (6,028) 1,266 (4,762) Realized loss on foreign currency hedges — 157 — 157 (33) 124 Realized gain on interest rate swap hedge — (1,847) — (1,847) 388 (1,459) Foreign currency translation loss — — (17,138) (17,138) — (17,138) September 27, 2019 $ (295) $ (4,279) $ 13,401 $ 8,827 $ 942 $ 9,769

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	9 Months Ended
	Oct. 02, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant October 2, 2020 Assets: Foreign currency contracts $ 98 $ — $ 98 $ — Liabilities: Foreign currency contracts 836 — 836 — Liabilities: Interest rate swaps 8,038 — 8,038 — Liabilities: Contingent consideration 5,401 — — 5,401 December 31, 2019 Assets: Foreign currency contracts $ 710 $ — $ 710 $ — Liabilities: Interest rate swaps 3,068 — 3,068 — Liabilities: Contingent consideration 4,200 — — 4,200 Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of October 2, 2020 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2020 Jun 2023 2.1785 % 0.1448 % $ (8,038) Other long-term liabilities (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2019 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2017 Jun 2020 1.1325 % 1.7920 % $ 543 Accrued expenses and other current liabilities 65,000 Jul 2019 Jul 2020 1.8900 1.7920 (72) Accrued expenses and other current liabilities 400,000 Apr 2019 Apr 2020 2.4150 1.7101 (730) Accrued expenses and other current liabilities 200,000 Jun 2020 Jun 2023 2.1785 (a) (2,809) Other long-term liabilities __________ (a) The interest rate swap did not take effect until June 2020. Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 7,666 Jul 2020 Dec 2020 0.0491 MXN Peso $ (519) Accrued expenses and other current liabilities 2,290 Mar 2020 Dec 2020 0.0241 UYU Peso (52) Prepaid expenses and other current assets 18,514 Nov 2020 Sep 2021 1.1944 Euro (274) Accrued expenses and other current liabilities 10,224 Jan 2021 Sep 2021 0.0454 MXN Peso (109) Accrued expenses and other current liabilities 2,343 Nov 2020 Nov 2020 1.1717 Euro 2 Accrued expenses and other current liabilities 2,656 Jan 2021 Mar 2021 0.0443 MXN Peso 64 Accrued expenses and other current liabilities 3,252 Jan 2021 Aug 2021 0.0232 UYU Peso 150 Prepaid expenses and other current assets Information regarding outstanding foreign currency contracts designated as cash flow hedges as of December 31, 2019 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 11,166 Jan 2020 Jun 2020 0.0490 MXN Peso $ 710 Prepaid expenses and other current assets
Schedule of Estimated Fair Values for Contingent Consideration	The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the nine months ended October 2, 2020 (in thousands): December 31, 2019 $ 4,200 Contingent consideration liabilities recorded for acquisitions 2,700 Fair value adjustment included in Other operating expenses (500) Settlements (1,000) Foreign currency translation 1 October 2, 2020 $ 5,401 As of October 2, 2020, the estimated fair value of the contingent consideration was $5.4 million, of which $1.2 million is included as current contingent consideration and $4.2 million is included in non-current contingent consideration in the Condensed Consolidated Balance Sheets. Derivative Instruments with Hedge Accounting Designation The following tables present the effect of cash flow hedge derivative instruments on other comprehensive income (loss) (“OCI”), AOCI and the Company’s Condensed Consolidated Statement of Operations for the three and nine months ended October 2, 2020 and September 27, 2019 (in thousands):
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	Three Months Ended October 2, 2020 September 27, 2019 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 235,942 $ 590 $ 303,587 $ (500) Cost of sales 178,009 (651) 210,201 309 Operating expenses 18,175 (23) 46,905 — Interest expense 9,368 (1,066) 12,337 444 Nine Months Ended October 2, 2020 September 27, 2019 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 804,483 $ 549 $ 932,457 $ (1,294) Cost of sales 591,985 (1,059) 653,477 1,137 Operating expenses 119,479 (57) 143,993 — Interest expense 29,002 (2,431) 39,779 1,847 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Unrealized Gain (Loss) Recognized in OCI Realized Gain (Loss) Reclassified from AOCI Three months ended, Location in Statement of Operations Three months ended, October 2, September 27, October 2, September 27, Interest rate swap $ (11) $ (991) Interest expense $ (1,066) $ 444 Foreign exchange forwards 68 (400) Sales 590 (500) Foreign exchange forwards 451 (68) Cost of sales (651) 309 Foreign exchange forwards 57 — Operating expenses (23) — Nine Months Ended Location in Statement of Operations Nine Months Ended October 2, September 27, October 2, September 27, Interest rate swaps $ (7,401) $ (6,590) Interest expense $ (2,431) $ 1,847 Foreign exchange contracts 277 (1,099) Sales 549 (1,294) Foreign exchange contracts (2,277) 1,661 Cost of sales (1,059) 1,137 Foreign exchange forwards (15) — Operating expenses (57) —
Schedule of Equity Method Investments	Equity investments comprise the following (in thousands): October 2, December 31, Equity method investment $ 19,718 $ 16,167 Non-marketable equity securities 6,092 6,092 Total equity investments $ 25,810 $ 22,259 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) The components of (Gain) Loss on Equity Investments, Net for each period were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Equity method investment income $ (2,234) $ (986) $ (3,954) $ (909) Impairment charges — — — 1,575 Total (gain) loss on equity investments, net $ (2,234) $ (986) $ (3,954) $ 666

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Oct. 02, 2020
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table presents sales from continuing operations by product line (in thousands). Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Segment sales from continuing operations by product line: Medical Cardio & Vascular $ 124,596 $ 148,581 $ 432,885 $ 451,552 Cardiac & Neuromodulation 72,909 106,533 252,404 337,932 Advanced Surgical, Orthopedics & Portable Medical 30,179 34,310 92,041 98,544 Total Medical 227,684 289,424 777,330 888,028 Non-Medical 8,258 14,163 27,153 44,429 Total sales from continuing operations $ 235,942 $ 303,587 $ 804,483 $ 932,457
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table presents income from continuing operations for the Company’s reportable segments (in thousands). Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Segment income from continuing operations: Medical $ 28,777 $ 62,648 $ 120,903 $ 182,734 Non-Medical 1,214 3,318 4,894 12,927 Total segment income 29,991 65,966 125,797 195,661 Unallocated operating income (expenses) (a) 9,767 (19,485) (32,778) (60,674) Operating income 39,758 46,481 93,019 134,987 Unallocated expenses, net (8,358) (10,982) (24,815) (39,524) Income from continuing operations before taxes $ 31,400 $ 35,499 $ 68,204 $ 95,463 __________ (a) Unallocated operating income (expenses) for the three and nine months ended October 2, 2020 includes a net gain of $28.2 million related to a patent litigation judgment. Refer to Note 10 “Commitments and Contingencies” for additional information on this matter.

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	9 Months Ended
	Oct. 02, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues. Three Months Ended October 2, 2020 September 27, 2019 Customer Medical Non-Medical Medical Non-Medical Customer A 16% * 20% * Customer B 17% * 18% * Customer C 17% * 13% * Customer D * 25% * 22% Customer F * 11% * * Customer G * * * 12% All other customers 50% 64% 49% 66% Nine Months Ended October 2, 2020 September 27, 2019 Customer Medical Non-Medical Medical Non-Medical Customer A 20% * 22% * Customer B 16% * 18% * Customer C 15% * 12% * Customer D * 22% * 24% Customer E * 11% * * All other customers 49% 67% 48% 76% __________ * Less than 10% of segment’s total revenues for the period. The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped.
Schedule of Revenue by Ship To Location	The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped. Three Months Ended October 2, 2020 September 27, 2019 Ship to Location Medical Non-Medical Medical Non-Medical United States 58% 66% 55% 61% South Korea * 11% * * Puerto Rico * * 11% * Canada * * * 12% All other countries 42% 23% 34% 27% (15.) REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued) Nine Months Ended October 2, 2020 September 27, 2019 Ship to Location Medical Non-Medical Medical Non-Medical United States 56% 54% 56% 58% Canada * 11% * 13% United Kingdom * 10% * * Puerto Rico * * 13% * All other countries 44% 25% 31% 29% __________ * Less than 10% of segment’s total revenues for the period.
Schedule of Contract with Customer, Asset and Liability	October 2, December 31, Contract assets $ 39,593 $ 24,767 Contract liabilities included in accrued expenses and other current liabilities 1,927 1,975

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Oct. 02, 2020
Discontinued Operations and Disposal Groups [Abstract]
Summary of discontinued operations	Income from discontinued operations net of taxes, were as follows (in thousands): Three Months Ended Nine Months Ended October 2, September 27, October 2, September 27, Gain on sale of discontinued operations $ — $ — $ — $ (4,974) Other income, net — — — (342) Provision for income taxes — — — 178 Income from discontinued operations $ — $ — $ — $ 5,138 Cash flow information from discontinued operations was as follows (in thousands): Nine Months Ended October 2, September 27, Cash used in operating activities $ — $ (58) Cash provided by investing activities — 4,734

Basis of Presentation (Narrativ

Basis of Presentation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Oct. 02, 2020	Oct. 02, 2020
Accounting Policies [Abstract]
Accounts receivable sold	$ 16.2	$ 47.1

Business Acquisitions (Acquisit

Business Acquisitions (Acquisition of Assets from InoMec Narrative) (Details) - USD ($) $ in Thousands	Feb. 19, 2020	Oct. 02, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill		$ 851,679	$ 839,617
InoMec Ltd
Business Acquisition [Line Items]
Consideration transferred	$ 7,000
Payments to acquire business	5,300
Fair value of contingent consideration recognized	1,700
Contingent consideration, range of outcomes, value, high	$ 3,500
Contingent consideration payment period	4 years
Intangible assets acquired	$ 2,000
Goodwill	4,800
Property, plant and equipment acquired	300
Other working capital items acquired	$ 100
Acquired finite-lived intangible assets, weighted average useful life	5 years 10 months 24 days

Business Acquisitions (Acquis_2

Business Acquisitions (Acquisition of Assets from US BioDesign Narrative) (Details) - USD ($) $ in Thousands	Oct. 07, 2019	Apr. 04, 2020	Oct. 02, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill			$ 851,679	$ 839,617
US BioDesign LLC
Business Acquisition [Line Items]
Consideration transferred	$ 19,100
Payments to acquire business	14,900
Consideration transferred working capital adjustment		$ 100
Liabilities incurred	4,200
Contingent consideration, range of outcomes, value, high	5,500
Goodwill	10,400
Property, plant and equipment acquired	700
Other working capital items acquired	600
Goodwill, working capital adjustment	100
Technology | US BioDesign LLC
Business Acquisition [Line Items]
Finite-lived intangibles acquired	$ 7,400
Useful life of acquired intangible asset	8 years

Business Acquisitions (Narrativ

Business Acquisitions (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Business Acquisition [Line Items]
Sales	$ 235,942	$ 303,587	$ 804,483	$ 932,457
InoMec Ltd And US BioDesign LLC
Business Acquisition [Line Items]
Sales	$ 2,200		5,400
Acquisition related costs			1,000
InoMec Ltd And US BioDesign LLC | Other operating expenses
Business Acquisition [Line Items]
Acquisition related costs			$ 900

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 3,756	$ 5,125
Supplemental lease disclosures:
Operating lease assets obtained in exchange for new or remeasured operating lease liabilities	$ 8,139	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 78,104	$ 79,742
Work-in-process	56,160	60,042
Finished goods	22,594	27,472
Total	$ 156,858	$ 167,256

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net (Schedule of Goodwill) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2020USD ($)
Goodwill [Roll Forward]
Opening goodwill	$ 839,617
Foreign currency translation	7,347
Goodwill, acquired during period	4,715
Closing goodwill	851,679
Medical
Goodwill [Roll Forward]
Opening goodwill	822,617
Foreign currency translation	7,347
Goodwill, acquired during period	4,715
Closing goodwill	834,679
Non-Medical
Goodwill [Roll Forward]
Opening goodwill	17,000
Foreign currency translation	0
Goodwill, acquired during period	0
Closing goodwill	$ 17,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net (Schedule of Definite-Lived and Indefinite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 975,167	$ 958,619
Accumulated amortization	(306,036)	(273,123)
Total estimated amortization expense	669,131	685,496
Trademarks And Tradenames
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	90,288	90,288
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	255,475	248,264
Accumulated amortization	(148,792)	(138,435)
Total estimated amortization expense	106,683	109,829
Customer lists
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	715,589	706,852
Accumulated amortization	(153,540)	(131,185)
Total estimated amortization expense	562,049	575,667
Other
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,103	3,503
Accumulated amortization	(3,704)	(3,503)
Total estimated amortization expense	$ 399	$ 0

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 03, 2020	Apr. 04, 2020	Oct. 02, 2020	Sep. 27, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Payments to acquire intangible assets			$ 4,607	$ 0
Gross carrying amount			975,167		$ 958,619
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount			255,475		$ 248,264
Purchased technology and patents | Non-Medical
Finite-Lived Intangible Assets [Line Items]
Payments to acquire intangible assets	$ 500	$ 3,500
Asset acquisition contingent consideration			500
Finite-lived intangible asset, acquisition costs capitalized			100
Gross carrying amount			$ 4,600
Intangible asset acquired, remaining amortization period			11 years

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 10,299	$ 9,782	$ 30,894	$ 29,467
Cost of sales
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	3,219	3,165	9,660	9,622
Selling, general and administrative expenses
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 7,080	$ 6,617	$ 21,234	$ 19,845

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) $ in Thousands	Oct. 02, 2020USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2020	$ 10,193
2021	41,186
2022	40,137
2023	38,720
2024	37,768
After 2024	$ 501,127

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Unamortized discount on term loan B and debt issuance costs	$ (8,241)	$ (10,702)
Total debt	839,107	814,772
Current portion of long-term debt	(37,500)	(37,500)
Total long-term debt	801,607	777,272
Secured Debt | Loans Payable | Term Loan A (TLA) Facility
Debt Instrument [Line Items]
Long-term debt, gross	239,062	267,188
Secured Debt | Loans Payable | Term Loan B (TLB) Facility
Debt Instrument [Line Items]
Long-term debt, gross	558,286	558,286
Secured Debt | Revolving Credit Facility | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Long-term debt, gross	$ 50,000	$ 0

Debt (Credit Facility) (Details

Debt (Credit Facility) (Details)	Jul. 13, 2020USD ($)	Apr. 02, 2021	Sep. 27, 2019USD ($)	Oct. 02, 2020USD ($)	Sep. 27, 2019USD ($)	Oct. 27, 2022
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 300,000		$ 1,300,000
Secured Debt | Revolving Credit Facility | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity				$ 200,000,000
Line of credit facility, remaining borrowing capacity				143,300,000
Letters of credit outstanding, amount				$ 50,000,000
Interest rate during period				2.41%
Secured Debt | Loans Payable | Term Loan B (TLB) Facility
Debt Instrument [Line Items]
Debt instrument, discount, percentage				1.00%
Debt weighted average interest rate				3.50%
Secured Debt | Loans Payable | Term Loan B (TLB) Facility | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread				1.50%
Secured Debt | Loans Payable | Term Loan B (TLB) Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread				2.50%
Debt instrument, interest rate, floor				1.00%
Secured Debt | Loans Payable | Term Loan A (TLA) Facility
Debt Instrument [Line Items]
Debt amendment fee				$ 400,000
Debt weighted average interest rate				2.40%
Debt instrument, covenant compliance, adjusted EBITDA to interest expense ratio				3
Net leverage ratio incremental increase option	0.50			4.75
Eligible adjustment acquisition threshold	$ 40,000,000
Deferred amendment fee, quarterly installment rate	0.03125%
Debt instrument, covenant compliance, maximum leverage ratio threshold for deferred amendment fee	3
Secured Debt | Loans Payable | Term Loan A (TLA) Facility | Forecast
Debt Instrument [Line Items]
Net leverage ratio incremental increase option		4.50				4
Secured Debt | Swingline Loans | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity				$ 15,000,000
Secured Debt | Standby Letters of Credit | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity				$ 25,000,000
Secured Debt | Minimum | Revolving Credit Facility | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage				0.175%
Secured Debt | Minimum | Loans Payable | Term Loan A (TLA) Facility | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread				0.50%
Secured Debt | Minimum | Loans Payable | Term Loan A (TLA) Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread				1.50%
Secured Debt | Maximum | Revolving Credit Facility | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage				0.25%
Secured Debt | Maximum | Loans Payable | Term Loan A (TLA) Facility | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread				2.00%
Secured Debt | Maximum | Loans Payable | Term Loan A (TLA) Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread				3.00%
Standby Letters of Credit | Revolving Credit Facility | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Letters of credit outstanding, amount				$ 6,700,000

Debt (Long-term Debt Maturity S

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Oct. 02, 2020USD ($)
Debt Disclosure [Abstract]
2020	$ 9,375
2021	37,500
2022	$ 800,473

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 2,987	$ 1,461	$ 6,229	$ 6,894
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	530	168	1,214	766
Selling, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	2,319	1,155	4,608	5,819
Research, development and engineering costs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	138	69	407	193
Other operating expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	0	69	0	116
Stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	10	101	33	304
RSUs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 2,977	$ 1,360	$ 6,196	$ 6,590

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Oct. 02, 2020USD ($)$ / sharesshares
Stock Option Activity (in shares)
Options outstanding, beginning balance (in shares) | shares	384,013
Exercised (in shares) | shares	(95,923)
Options outstanding, ending balance (in shares) | shares	288,090
Options exercisable at period end (in shares) | shares	285,540
Weighted Average Exercise Price (in dollars per share)
Options outstanding, beginning (in dollars per share) | $ / shares	$ 34.96
Exercised (in dollars per share) | $ / shares	32.56
Options outstanding, ending (in dollars per share) | $ / shares	35.76
Options exercisable at period end (in dollars per share) | $ / shares	$ 35.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	4 years 10 months 24 days
Options exercisable, weighted average remaining contractual term	4 years 10 months 24 days
Options outstanding, intrinsic value | $	$ 6.3
Options exercisable, intrinsic value | $	$ 6.3

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - Restricted Stock And Restricted Stock Units Time Based	9 Months Ended
	Oct. 02, 2020installment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments for vesting	4
Requisite service period	3 years

Stock-Based Compensation (Valua

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average illiquidity discount	8.00%
Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value (in dollars per share)	$ 107.27	$ 117.03
Risk-free interest rate	1.29%	2.46%
Expected volatility	30.00%	40.00%
Expected life (in years)	2 years 10 months 24 days	2 years 9 months 18 days
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	9 Months Ended
	Oct. 02, 2020$ / sharesshares
Restricted Stock And Restricted Stock Units Time Based
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, beginning (in shares) | shares	205,223
Granted (in shares) | shares	143,122
Vested (in shares) | shares	(83,469)
Forfeited (in shares) | shares	(12,343)
Nonvested, ending (in shares) | shares	252,533
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, beginning (in dollars per share) | $ / shares	$ 64.75
Granted (in dollars per share) | $ / shares	83.94
Vested (in dollars per share) | $ / shares	59.60
Forfeited (in dollars per share) | $ / shares	75.28
Nonvested, ending (in dollars per share) | $ / shares	$ 76.81
Performance-based RSUs (PSUs)
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, beginning (in shares) | shares	191,592
Granted (in shares) | shares	67,268
Vested (in shares) | shares	(35,363)
Forfeited (in shares) | shares	(4,106)
Nonvested, ending (in shares) | shares	219,391
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, beginning (in dollars per share) | $ / shares	$ 56.30
Granted (in dollars per share) | $ / shares	95.06
Vested (in dollars per share) | $ / shares	31.17
Forfeited (in dollars per share) | $ / shares	51.54
Nonvested, ending (in dollars per share) | $ / shares	$ 72.33

Other Operating Expenses (Sched

Other Operating Expenses (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 2,674	$ 2,241	$ 7,631	$ 8,239
Strategic reorganization and alignment
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	0	962	686	4,352
Manufacturing alignment to support growth
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	36	515	224	1,661
2020 restructuring plan
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	858	0	2,275	0
Acquisition and integration expenses
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	107	0	510	0
Other general expenses
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 1,673	$ 764	$ 3,936	$ 2,226

Other Operating Expenses (Narra

Other Operating Expenses (Narrative) (Details) $ in Millions	9 Months Ended
	Oct. 02, 2020USD ($)
InoMec Ltd And US BioDesign LLC
Restructuring Cost and Reserve [Line Items]
Acquisition related costs	$ 1
US BioDesign LLC
Restructuring Cost and Reserve [Line Items]
Contingent consideration liabilities recorded for acquisitions	0.5
2020 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	2.3
2020 Restructuring Plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected costs	2
2020 Restructuring Plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected costs	3
Strategic Reorganization And Alignment
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	23
Manufacturing Alignment To Support Growth
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	5.8
Expected costs	$ 6

Other Operating Expenses (Sch_2

Other Operating Expenses (Schedule of Restructuring Reserve By Type of Cost) (Details) - Consolidation And Optimization Initiatives $ in Thousands	9 Months Ended
	Oct. 02, 2020USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 1,985
Restructuring charges	3,185
Cash payments	(5,002)
Ending balance	168
Severance and Retention
Restructuring Reserve [Roll Forward]
Beginning balance	1,389
Restructuring charges	2,166
Cash payments	(3,483)
Ending balance	72
Other
Restructuring Reserve [Roll Forward]
Beginning balance	596
Restructuring charges	1,019
Cash payments	(1,519)
Ending balance	$ 96

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019	Jul. 03, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	3.40%	13.80%	9.30%	16.00%
Income (loss) before provision for income taxes	$ 31,400	$ 35,499	$ 68,204	$ 95,463
Discrete tax benefits	4,900	$ 2,300	5,900	$ 4,400
Unrecognized tax benefits	5,000		5,000			$ 4,400
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit	3,900		3,900
Unrecognized tax benefits that would impact effective tax rate	5,000		5,000			$ 4,400
Accrued Payroll Taxes	$ 6,500		$ 6,500		$ 6,500

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	Oct. 26, 2020	Oct. 15, 2020	Jan. 26, 2016	Oct. 02, 2020	Oct. 02, 2020
Gain Contingencies [Line Items]
Gain contingency, asset				$ 28.9	$ 28.9
Accrued professional fees				0.7	0.7
Gain related to litigation settlement				$ 28.2	$ 28.2
Product warranty description					The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Subsequent Event
Gain Contingencies [Line Items]
Proceeds from legal settlements	$ 0.6	$ 28.3
Positive Outcome of Litigation
Gain Contingencies [Line Items]
Amount awarded from other party			$ 27.8

Commitments and Contingencies_3

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	9 Months Ended
	Oct. 02, 2020USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 1,933
Additions to warranty reserve, net of reversals	(156)
Adjustments to pre-existing warranties	(119)
Warranty claims settled	(1,323)
Balance at end of period	$ 335

Earnings Per Share (EPS) (Detai

Earnings Per Share (EPS) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Earnings Per Share [Abstract]
Income from continuing operations	$ 30,342	$ 30,586	$ 61,831	$ 80,174
Income from discontinued operations	0	0	0	5,138
Net income	$ 30,342	$ 30,586	$ 61,831	$ 85,312
Denominator for basic and diluted EPS:
Weighted average shares outstanding, basic (in shares)	32,859	32,660	32,833	32,606
Dilutive effect of share-based awards (in shares)	217	408	274	413
Weighted average shares outstanding - Diluted (in shares)	33,076	33,068	33,107	33,019
Basic earnings per share:
Income from continuing operations (in dollars per share)	$ 0.92	$ 0.94	$ 1.88	$ 2.46
Income from discontinued operations (in dollars per share)	0	0	0	0.16
Basic earnings per share (in dollars per share)	0.92	0.94	1.88	2.62
Diluted earnings per share:
Income from continuing operations (in dollars per share)	0.92	0.92	1.87	2.43
Income from discontinued operations (in dollars per share)	0	0	0	0.16
Diluted earnings per share (in dollars per share)	$ 0.92	$ 0.92	$ 1.87	$ 2.58
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, RSAs and RSUs (in shares)	145	0	134	29
Performance-vested restricted stock and PRSUs (in shares)	167	50	93	48

Stockholders' Equity (Details)

Stockholders' Equity (Details) - shares	9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	32,847,017
Shares outstanding beginning balance (in shares)	32,700,471	32,473,167
Stock options exercised (in shares)	95,923	116,904
Balance, end of period (in shares)	32,875,166
Shares outstanding ending balance (in shares)	32,875,166	32,668,627
Common Stock
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	32,847,017	32,624,494
Stock options exercised (in shares)	21,327	116,904
Balance, end of period (in shares)	32,875,166	32,841,183
Treasury Stock, Common
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	146,546	151,327
Stock options exercised (in shares)	74,596	0
Balance, end of period (in shares)	0	172,556
Restricted Stock
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	78,772	78,556
Restricted Stock | Common Stock
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	6,822	99,785
Restricted Stock | Treasury Stock, Common
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	71,950	(21,229)

Stockholders' Equity Accumulate

Stockholders' Equity Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	$ 1,181,401	$ 1,111,695	$ 1,152,488	$ 1,060,493
Reclassification from AOCI, tax	0	0	0	0
Reclassification from AOCI, net of tax	16,387	(14,810)	17,303	(17,138)
Balance, ending balance	1,232,997	1,128,578	1,232,997	1,128,578
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, tax	(118)	307	1,978	1,266
Reclassification from AOCI, net of tax	447	(1,152)	(7,438)	(4,762)
Interest rate swap
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, tax	(224)	93	(511)	388
Reclassification from AOCI, net of tax	842	(351)	1,920	(1,459)
Foreign exchange contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, tax	(18)	(40)	(119)	(33)
Reclassification from AOCI, net of tax	66	151	448	124
Defined Benefit Plan Liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	(912)	(295)	(912)	(295)
Balance, ending balance	(912)	(295)	(912)	(295)
Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	(10,491)	(2,567)	(2,358)	3,439
Balance, ending balance	(8,776)	(4,279)	(8,776)	(4,279)
Cash Flow Hedges | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	565	(1,459)	(9,416)	(6,028)
Cash Flow Hedges | Interest rate swap
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	1,066	(444)	2,431	(1,847)
Cash Flow Hedges | Foreign exchange contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	84	191	567	157
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	23,555	28,211	22,639	30,539
Reclassification from AOCI, before tax	16,387	(14,810)	17,303	(17,138)
Balance, ending balance	39,942	13,401	39,942	13,401
Total Pre-Tax Amount
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	12,152	25,349	19,369	33,683
Reclassification from AOCI, before tax	16,387	(14,810)	17,303	(17,138)
Balance, ending balance	30,254	8,827	30,254	8,827
Total Pre-Tax Amount | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	565	(1,459)	(9,416)	(6,028)
Total Pre-Tax Amount | Interest rate swap
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	1,066	(444)	2,431	(1,847)
Total Pre-Tax Amount | Foreign exchange contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, before tax	84	191	567	157
Tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	2,327	582	619	(679)
Balance, ending balance	1,967	942	1,967	942
Net-of-Tax Amount
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, beginning of period	14,479	25,931	19,988	33,004
Balance, ending balance	$ 32,221	$ 9,769	$ 32,221	$ 9,769

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	$ 98	$ 710
Liabilities: Foreign currency contracts	836
Liabilities: Interest rate swaps	8,038	3,068
Liabilities: Contingent consideration	5,401	4,200
Quoted Prices in Active Markets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	0	0
Liabilities: Foreign currency contracts	0
Liabilities: Interest rate swaps	0	0
Liabilities: Contingent consideration	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	98	710
Liabilities: Foreign currency contracts	836
Liabilities: Interest rate swaps	8,038	3,068
Liabilities: Contingent consideration	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	0	0
Liabilities: Foreign currency contracts	0
Liabilities: Interest rate swaps	0	0
Liabilities: Contingent consideration	$ 5,401	$ 4,200

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Interest Rate Swap Maturing June 2020 | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount		$ 200,000
Pay Fixed Rate		1.1325%
Receive Current Floating Rate		1.792%
Fair Value		$ 543
Interest Rate Swap Maturing July 2020 | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount		$ 65,000
Pay Fixed Rate		1.89%
Receive Current Floating Rate		1.792%
Fair Value		$ (72)
Interest Rate Swap Maturing April 2020 | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount		$ 400,000
Pay Fixed Rate		2.415%
Receive Current Floating Rate		1.7101%
Fair Value		$ (730)
Interest Rate Swap Maturing June 2023 | Other long-term liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 200,000	$ 200,000
Pay Fixed Rate	2.1785%	2.1785%
Receive Current Floating Rate	0.1448%
Fair Value	$ (8,038)	$ (2,809)

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) - Designated as Hedging Instrument $ in Thousands	Oct. 02, 2020USD ($)$ / $$ / $$ / €	Dec. 31, 2019USD ($)$ / $
Foreign Exchange Contract Maturing December 2020, Contract One | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 7,666
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0491
Fair Value	$ (519)
Foreign Exchange Contract Maturing December 2020, Contract Two | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 2,290
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0241
Fair Value	$ (52)
Foreign Exchange Contract Maturing September 2021, Contract One | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 18,514
$/Foreign currency (in dollars per foreign currency) | $ / €	1.1944
Fair Value	$ (274)
Foreign Exchange Contract Maturing September 2021, Contract Two | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 10,224
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0454
Fair Value	$ (109)
Foreign Exchange Contract Maturing November 2020 | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 2,343
$/Foreign currency (in dollars per foreign currency) | $ / €	1.1717
Fair Value	$ 2
Foreign Exchange Contract Maturing March 2021 | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 2,656
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0443
Fair Value	$ 64
Foreign Exchange Contract Maturing August 2021 | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount	$ 3,252
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0232
Fair Value	$ 150
Foreign Exchange Contract Maturing June 2020 | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 11,166
$/Foreign currency (in dollars per foreign currency) | $ / $		0.0490
Fair Value		$ 710

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($)	6 Months Ended	9 Months Ended
	Oct. 02, 2020	Oct. 02, 2020	Apr. 04, 2020	Feb. 19, 2020	Dec. 31, 2019	Oct. 07, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset acquisition contingent consideration recognized			$ 1,000,000
Settlements	$ 500,000	$ 1,000,000
Fair value	5,401,000	5,401,000			$ 4,200,000
Derivative instruments net loss to be reclassified to net income during next twelve months		4,300,000
Accrued expenses and other current liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	1,200,000	1,200,000
Other long-term liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 4,200,000	$ 4,200,000
Chinese Venture Capital Fund
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity method investment ownership (percent)	6.60%	6.60%
InoMec Ltd
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, range of outcomes, value, low				$ 0
Contingent consideration, range of outcomes, value, high				3,500,000
Fair value of contingent consideration recognized				$ 1,700,000
Business acquisition contingent liability	$ 1,700,000	$ 1,700,000
US BioDesign LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, range of outcomes, value, low						$ 0
Contingent consideration, range of outcomes, value, high						5,500,000
Fair value of contingent consideration recognized						$ 4,200,000
Contingent consideration liabilities recorded for acquisitions		500,000
Business acquisition contingent liability	$ 3,700,000	$ 3,700,000

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) - USD ($) $ in Thousands	6 Months Ended	9 Months Ended
	Oct. 02, 2020	Oct. 02, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period		$ 4,200
Contingent consideration liabilities recorded for acquisitions		2,700
Fair value adjustment included in Other operating expenses		(500)
Settlements	$ (500)	(1,000)
Foreign currency translation		1
Balance at end of period	$ 5,401	$ 5,401

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measurements (Impact of Cash Flow Hedges on Other Comprehensive Income, AOCI and the Condensed Consolidated Statements of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Interest expense
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	$ (1,066)	$ 444	$ (2,431)	$ 1,847
Interest expense | Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	(11)	(991)	(7,401)	(6,590)
Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	590	(500)	549	(1,294)
Sales | Foreign exchange forwards
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	68	(400)	277	(1,099)
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	(651)	309	(1,059)	1,137
Cost of sales | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	451	(68)	(2,277)	1,661
Operating expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	(23)	0	(57)	0
Operating expenses | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	$ 57	$ 0	$ (15)	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Equity method investment	$ 19,718		$ 19,718		$ 16,167
Non-marketable equity securities	6,092		6,092		6,092
Total equity investments	25,810		25,810		$ 22,259
Equity method investment income	(2,234)	$ (986)	(3,954)	$ (909)
Impairment charges	0	0	0	1,575
Total (gain) loss on equity investments, net	$ (2,234)	$ (986)	$ (3,954)	$ 666

Segment Information (Narrative)

Segment Information (Narrative) (Details)	9 Months Ended
	Oct. 02, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information (Reconcilia

Segment Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	$ 235,942	$ 303,587	$ 804,483	$ 932,457
Operating Segments | Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	227,684	289,424	777,330	888,028
Operating Segments | Medical | Cardio & Vascular
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	124,596	148,581	432,885	451,552
Operating Segments | Medical | Cardiac & Neuromodulation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	72,909	106,533	252,404	337,932
Operating Segments | Medical | Advanced Surgical, Orthopedics & Portable Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	30,179	34,310	92,041	98,544
Operating Segments | Non-Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales from continuing operations	$ 8,258	$ 14,163	$ 27,153	$ 44,429

Segment Information (Reconcil_2

Segment Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Segment Reporting Information [Line Items]
Operating income	$ 39,758	$ 46,481	$ 93,019	$ 134,987
Unallocated expenses, net	(8,358)	(10,982)	(24,815)	(39,524)
Income from continuing operations before taxes	31,400	35,499	68,204	95,463
Gain related to litigation settlement	28,200		28,200
Operating Segments
Segment Reporting Information [Line Items]
Operating income	29,991	65,966	125,797	195,661
Operating Segments | Medical
Segment Reporting Information [Line Items]
Operating income	28,777	62,648	120,903	182,734
Operating Segments | Non-Medical
Segment Reporting Information [Line Items]
Operating income	1,214	3,318	4,894	12,927
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income	$ 9,767	$ (19,485)	$ (32,778)	$ (60,674)

Revenue From Contracts With C_3

Revenue From Contracts With Customers (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Revenue from Contract with Customer [Abstract]
Percent of revenue from contract with customer compared to total revenue	30.00%	10.00%	29.00%	11.00%
Contract assets, increase due to new contract			$ 14.8
Revenue recognized that was included in contract liability balance at beginning of period	$ 0.2	$ 0.4	$ 1.3	$ 0.8

Revenue From Contracts With C_4

Revenue From Contracts With Customers (Disaggregated Revenue) (Details) - Revenue from contract with customer benchmark - Customer Concentration Risk	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Medical | Customer A
Disaggregation of Revenue [Line Items]
Concentration risk percentage	16.00%	20.00%	20.00%	22.00%
Medical | Customer B
Disaggregation of Revenue [Line Items]
Concentration risk percentage	17.00%	18.00%	16.00%	18.00%
Medical | Customer C
Disaggregation of Revenue [Line Items]
Concentration risk percentage	17.00%	13.00%	15.00%	12.00%
Medical | All other customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	50.00%	49.00%	49.00%	48.00%
Non-Medical | Customer D
Disaggregation of Revenue [Line Items]
Concentration risk percentage	25.00%	22.00%	22.00%	24.00%
Non-Medical | Customer E
Disaggregation of Revenue [Line Items]
Concentration risk percentage			11.00%
Non-Medical | Customer F
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%
Non-Medical | Customer G
Disaggregation of Revenue [Line Items]
Concentration risk percentage		12.00%
Non-Medical | All other customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	64.00%	66.00%	67.00%	76.00%

Revenue From Contracts With C_5

Revenue From Contracts With Customers (Schedule of Revenue by Ship To Location) (Details) - Geographic Concentration Risk - Revenue from contract with customer benchmark	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Medical Segment | United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	58.00%	55.00%	56.00%	56.00%
Medical Segment | Puerto Rico
Disaggregation of Revenue [Line Items]
Concentration risk percentage		11.00%		13.00%
Medical Segment | All other countries
Disaggregation of Revenue [Line Items]
Concentration risk percentage	42.00%	34.00%	44.00%	31.00%
Non-Medical Segment | United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	66.00%	61.00%	54.00%	58.00%
Non-Medical Segment | South Korea
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%
Non-Medical Segment | Canada
Disaggregation of Revenue [Line Items]
Concentration risk percentage		12.00%	11.00%	13.00%
Non-Medical Segment | United Kingdom
Disaggregation of Revenue [Line Items]
Concentration risk percentage			10.00%
Non-Medical Segment | All other countries
Disaggregation of Revenue [Line Items]
Concentration risk percentage	23.00%	27.00%	25.00%	29.00%

Revenue From Contracts With C_6

Revenue From Contracts With Customers Contract with Customer (Assets and Liability) (Details) - USD ($) $ in Thousands	Oct. 02, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Contract assets	$ 39,593	$ 24,767
Contract liabilities included in accrued expenses and other current liabilities	$ 1,927	$ 1,975

Discontinued Operations (Assets

Discontinued Operations (Assets and Liabilities of Viant Business) (Details) - Discontinued Operations, Held-for-sale - AS&O Business - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 28, 2019	Sep. 27, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from transition services		$ 2.9
Transition services, cost of sales		0.1
Transition services, selling, general and administrative		$ 2.8
Net working capital adjustment	$ 4.8

Discontinued Operations (Gain f

Discontinued Operations (Gain from Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2020	Sep. 27, 2019	Oct. 02, 2020	Sep. 27, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Provision for income taxes	$ 0	$ 0	$ 0	$ 178
Income from discontinued operations	0	0	0	5,138
AS&O Business | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of discontinued operations	0	0	0	(4,974)
Other income, net	0	0	0	(342)
Provision for income taxes	0	0	0	178
Income from discontinued operations	$ 0	$ 0	0	5,138
Cash used in operating activities			0	(58)
Cash provided by investing activities			$ 0	$ 4,734

Uncategorized Items - gb-202010

Label	Element	Value
Accounting Standards Update [Extensible List]	us-gaap_AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201602Member